TGFB1 and Miyoshi myopathy: If the impact of TGF-β on the immune and metabolic microenvironment in MM can be more clearly defined, it’s expected to overcome the prevailing dilemma of treating MM, boost the remission rate, and decrease the recurrence rate of MM [3, 7].